Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer

Urology

Volumn 64, Issue 1, 2004, Pages 128-131

  Miyaji, Yoshiyuki ^a   Saika, Takashi ^a,b   Yamamoto, Yasuo ^a   Kusaka, Nobuyuki ^a   Arata, Ryoji ^a   Ebara, Shin ^a   Nasu, Yasutomo ^a   Tsushima, Tomoyasu ^a   Kumon, Hiromi ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE METASTASIS; BONE MINERAL; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MALE; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE REMODELING; BONE RESORPTION; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; OSTEOPOROSIS; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 3042696410     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.03.012     Document Type: Article

References (22)

1. Daniell W.H. Osteoporosis after orchiectomy for prostate cancer. J Urol. 157:1977;439-444
2. Seeley D.G., Browner W.S., Nevitt M.C., et al. for the Study of Osteoporotic Fractures Research Group Which fractures are associated with low appendicular bone mass in elderly women? Ann Intern Med. 115:1991;837-842
3. Cummings S.R., Black D.M., Nevitt M.C., et al. for the Study of Osteoporotic Fractures Research Group Bone density at various sites for prediction of hip fractures. Lancet. 341:1993;72-75
4. Orwoll E.S. Osteoporosis in men. Endocrinol Metab Clin North Am. 27:1998;349-367
5. Townsend M.F., Sanders W.H., Northway R.O., et al. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer. 79:1997;545-550
6. Berruti A., Dogliotti L., Bitossi R., et al. Incidence of skeletal complications in patients with bone metastatic cancer and hormone refractory disease, predictive role of bone resorption and formation markers evaluated at baseline. J Urol. 164:2000;1248-1253
7. Wei J.T., Gross M., Jaffe C.A., et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology. 54:1999;607-611
8. Daniell H.W., Dunn S.R., Ferguson D.W., et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 163:2000;181-186
9. Kiratli B.J., Srinivas S., Perkash I., et al. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology. 57:2001;127-132
10. Stoch S.A., Parker R.A., Chen L., et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab. 86:2001;2787-2791
11. Oefelein M.G., Ricchuiti V., Conrad W., et al. Skeletal fracture associated with androgen suppression induced osteoporosis, the clinical incidence and risk factors for patients with prostate cancer. J Urol. 166:2001;1724-1728
12. Genant HK, Engelke K, Fuerst T, et al. Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res 11: 707-730, 1996
13. Taubman M.B., Goldberg B., Sherr C.J. Radioimmunoassay for human pro-collagen. Science. 186:1974;1115-1117
14. Melkko J., Niemi S., Risteli L., et al. Radioimmunoassay of carboxy-terminal propeptide of human type I procollagen. Clin Chem. 36:1990;1328-1332
15. Risteli J., Elomaa I., Niemi S., et al. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type-I collagen new serum marker of bone collagen degradation. Clin Chem. 39:1993;635-640
16. Yasumizu T., Okuno T., Fukada Y., et al. Age-related changes in bone mineral density and serum bone-related proteins in premenopausal and postmenopausal Japanese women. Endocr J. 47:2000;103-109
17. Yasumizu T., Fukada Y., Hoshi K. Changes in serum levels of type I collagen-related proteins after surgically induced menopause and correlations with bone loss in the lumbar spine. Endocr J. 46:1999;337-343
18. Hoshino H., Kushida K., Takahashi M., et al. Characteristics of biochemical markers in patients with metabolic bone disorders. Endocr Res. 24:1998;55-64
19. Maheux R. Treatment of fibroids with the combination of the GnRH agonist goserelin (Zoladex) and hormone replacement therapy. Adv Reprod Endocrinol. 4:1992;135-146
20. Johansen J.S., Riis B.J., Hassager C., et al. The effect of a gonadotropin-releasing hormone agonist analog (Nafarelin) on bone metabolism. J Clin Endocrinol Metab. 67:1988;701-706
21. 3. J Clin Endocrinol Metab. 70:1990;1055-1056
22. Matta W.H., Shaw R.W., Hesp R., et al. Hypogonadism induced by luteinising hormone releasing hormone agonist analogues effects on bone density in premenopausal women. BMJ. 294:1987;1523-1524